| Current Price | $2.61 | Mkt Cap | $334.6M |
|---|---|---|---|
| Open | $2.72 | P/E Ratio | -2.09 |
| Prev. Close | $2.61 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $2.60 - $2.74 | Volume | 100 |
| 52-Wk Range | $2.60 - $9.49 | Avg. Daily Vol. | 2,091,362 |
| Current Price | $2.61 | Mkt Cap | $334.6M |
|---|---|---|---|
| Open | $2.72 | P/E Ratio | -2.09 |
| Prev. Close | $2.61 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $2.60 - $2.74 | Volume | 100 |
| 52-Wk Range | $2.60 - $9.49 | Avg. Daily Vol. | 2,091,362 |
The best Bull and Bear pitches based on recency and number of recommendations.
Seres Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $15.33, a 155.5% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $15 price… More
I was hoping CAPS would have Seres ratable on the day of their ridiculous IPO, when the shares were priced at 18, opened at 29, and rose to 51. Alas, as far as MF was concerned, MCRB meant McRib and I didn't feel like shorting fast food. Seres is… More
Read the most recent pitches from players about MCRB.
Recs
MujamMojam
(< 20)
Submitted: 1/16/2020 1:11:24 AM :
Start Price:
$3.05
NASDAQ:MCRB Score:
-44.52
Seres Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $15.33, a 155.5% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $15 price target.
https://theenterpriseleader.com/2019/11/24/seres-therapeutics-nasdaqmcrb-earns-buy-rating-from-hc-wainwright.html
..Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.03. The firm had revenue of $7.03 million during the quarter, compared to analyst estimates of $6.69 million. On average, sell-side analysts forecast that Seres Therapeutics will post -1.43 EPS for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Nikko Asset Management Americas Inc. grew its position in Seres Therapeutics by 58.2% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 7,661,963 shares of the biotechnology company’s stock worth $30,724,000 after purchasing an additional 2,818,889 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its position in Seres Therapeutics by 58.2% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,661,963 shares of the biotechnology company’s stock worth $30,724,000 after purchasing an additional 2,818,889 shares during the last quarter. ARK Investment Management LLC grew its position in Seres Therapeutics by 33.1% in the 2nd quarter. ARK Investment Management LLC now owns 7,038,885 shares of the biotechnology company’s stock worth $22,665,000 after purchasing an additional 1,751,172 shares during the last quarter. Perceptive Advisors LLC acquired a new stake in Seres Therapeutics in the 2nd quarter worth $8,050,000. Finally, BlackRock Inc. grew its position in Seres Therapeutics by 5.6% in the 2nd quarter. BlackRock Inc. now owns 2,323,332 shares of the biotechnology company’s stock worth $7,480,000 after purchasing an additional 122,803 shares during the last quarter. Institutional investors own 98.37% of the company’s stock.
Find the members with the highest scoring picks in MCRB.
DaytradingStars (36.84) Score: +278.23
The Score Leader is the player with the highest score across all their picks in MCRB.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| ChanceClub | 80.25 | 8/17/2020 |
|
5Y | $27.50 | -90.45% | +27.36% | +117.82 | 0 Comment | |
| jackbot | 97.28 | 8/10/2020 |
|
5Y | $21.02 | -87.51% | +28.53% | +116.05 | 0 Comment | |
| RANEsq | 69.58 | 9/3/2020 |
|
5Y | $25.21 | -89.59% | +20.95% | +110.54 | 0 Comment | |
| whatsthepoint | 99.99 | 8/3/2020 |
|
5Y | $4.13 | -36.44% | +30.74% | +67.18 | 0 Comment | |
| SnPee500 | 72.11 | 8/19/2021 |
|
5Y | $6.20 | -57.66% | -1.34% | +56.32 | 0 Comment | |
| Under5b | < 20 | 9/12/2023 |
|
5Y | $3.03 | -13.22% | -3.59% | +9.63 | 0 Comment | |
| MujamMojam | < 20 | 1/16/2020 |
|
3Y | $3.05 | -13.93% | +30.58% | -44.52 | 1 Comment | |
| kkconway | 98.96 | 6/27/2023 |
|
5Y | $5.33 | -50.70% | -1.27% | -49.44 | 0 Comment | |
| jboudos | 56.53 |
|
|
1Y | $7.91 | -66.81% | -5.52% | -61.29 | 0 Comment | |
| jeepdrew222 | 39.26 | 12/30/2019 |
|
5Y | $4.05 | -35.19% | +33.28% | -68.46 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
